Dysfunctional TLR1 reduces the therapeutic efficacy of chemotherapy by attenuating HMGB1-mediated antitumor immunity in locally advanced colorectal cancer.

MLA

Huang, Kevin Chih-Yang, et al. “Dysfunctional TLR1 Reduces the Therapeutic Efficacy of Chemotherapy by Attenuating HMGB1-Mediated Antitumor Immunity in Locally Advanced Colorectal Cancer.” Scientific Reports, vol. 13, no. 1, Nov. 2023, p. 19440. EBSCOhost, https://doi.org/10.1038/s41598-023-46254-1.

APA

Huang, K. C.-Y., Ke, T.-W., Chen, J.-Y., Hong, W.-Z., Chiang, S.-F., Lai, C.-Y., Chen, T.-W., Yang, P.-C., Chen, L.-C., Liang, J.-A., Chen, W. T.-L., & Chao, K. S. C. (2023). Dysfunctional TLR1 reduces the therapeutic efficacy of chemotherapy by attenuating HMGB1-mediated antitumor immunity in locally advanced colorectal cancer. Scientific Reports, 13(1), 19440. https://doi.org/10.1038/s41598-023-46254-1

Chicago

Huang, Kevin Chih-Yang, Tao-Wei Ke, Jia-Yi Chen, Wei-Ze Hong, Shu-Fen Chiang, Chia-Ying Lai, Tsung-Wei Chen, et al. 2023. “Dysfunctional TLR1 Reduces the Therapeutic Efficacy of Chemotherapy by Attenuating HMGB1-Mediated Antitumor Immunity in Locally Advanced Colorectal Cancer.” Scientific Reports 13 (1): 19440. doi:10.1038/s41598-023-46254-1.